Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
1. Evogliptin 5mg Group: Administration with Evogliptin 5mg and Placebo for 24weeks 2. Pioglitazone 15mg Group: Administration with Pioglitazone 15mg and Placebo for 24weeks
Epistemonikos ID: ef1ec5e7043ca48d7835a9626b66b10ccac035f1
First added on: May 22, 2024